Sign In
Buy ATI
$197.80
-2.04 (-1.02%)
At Close: Jul 24, 2026
ATI (ATI) Is Considered a Good Investment by Brokers: Is That True?
10:31am, Thursday, 25'th Sep 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
ATI (ATI) Stock Sinks As Market Gains: Here's Why
07:15pm, Monday, 22'nd Sep 2025
ATI (ATI) closed at $79.87 in the latest trading session, marking a -1.07% move from the prior day.
ATI (ATI) Advances While Market Declines: Some Information for Investors
07:01pm, Tuesday, 16'th Sep 2025
In the latest trading session, ATI (ATI) closed at $79.47, marking a +2.61% move from the previous day.
ATI (ATI) Surpasses Market Returns: Some Facts Worth Knowing
07:01pm, Wednesday, 10'th Sep 2025
ATI (ATI) closed the most recent trading day at $76.39, moving +2.02% from the previous trading session.
ATI names aerospace leaders to Board to drive growth
07:32am, Wednesday, 10'th Sep 2025
Appointments of experienced leaders strengthen ATI's position as aerospace and defense leader DALLAS , Sept. 10, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced the appointment of two proven
ATI Chief Financial Officer Don Newman Announces Retirement
07:30am, Wednesday, 10'th Sep 2025
Search for successor underway DALLAS , Sept. 10, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) today announced that Executive Vice President - Finance and Chief Financial Officer Don Newman has informed t
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
07:20am, Tuesday, 09'th Sep 2025
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat Appili Non-Clinical Director to join NATO a
- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: AC
Why Allegheny Technologies (ATI) is a Top Momentum Stock for the Long-Term
06:06pm, Monday, 08'th Sep 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Mesirow Advises ATI on the Sale of ATI's East Hartford Operations to Barnes Aerospace
11:00am, Wednesday, 13'th Aug 2025
East Hartford Operations is a leading supplier of flight-safety critical components and assemblies for the commercial and defense aerospace sectors. Mesirow acted as the exclusive financial advisor on
ATI's Q2 Earnings Beat Estimates on Aerospace & Defense Gains
11:31am, Thursday, 07'th Aug 2025
ATI's Q2 earnings top estimates as strength in aerospace and defense drives solid gains in the HPMC segment EBITDA.
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
07:21am, Wednesday, 06'th Aug 2025
Peer-reviewed publication highlights ATI-1701's robust protection against aerosolized Francisella tularensis exposure in multiple animal models
Ati (ATI) Fiscal Q2 EPS Jumps 23%
11:54pm, Friday, 01'st Aug 2025
Ati (ATI) Fiscal Q2 EPS Jumps 23%
ATI Physical Therapy Goes Private
10:35am, Friday, 01'st Aug 2025
ATI Physical Therapy Transitions from Public to Private Ownership Move to Private Ownership Supports Long-Term Growth, Operational Flexibility, and Continued Focus on Patient Care DOWNERS GROVE, Ill.
ATI Inc. (ATI) Q2 2025 Earnings Call Transcript
12:40pm, Thursday, 31'st Jul 2025
ATI Inc. (NYSE:ATI ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants David Weston - Vice President of Investor Relations Donald P. Newman - Executive VP of Finance & CFO
